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Abstract 
Background: RBC membrane derived nanoparticles (NPs) represent an emerging platform with prolonged circu-
lation capacity for the delivery of active substances. For functionalize derived RBCs NPs, various strategies, such as 
biomimetic rebuilding of RBCs, chemical modification or inserting ligands, have been carried out to improve their 
performance. However, one potential adverse effect for these methods is the structural failure of membrane proteins, 
consequently affecting its original immune escape function.
Results: In this study, we reported a green technology of “disassembly-reassembly” to prepare biomimetic reconsti-
tuted RBCs membrane (rRBCs) by separating the endogenous proteins and lipids from nature RBC membrane. IR780 
iodide was used as a pattern drug to verify the property and feasibility of rRBCs by constructing IR780@rRBC NPs with 
IR780@RBC NPs and free IR780 as controls. The results demonstrated the superiority of IR780@rRBC NPs in toxicity, 
stability, pharmacokinetics and pharmacodynamics compared with IR780@rRBC and free IR780.
Conclusions: The reported “disassembly-reassembly” strategy shows great potential to produce controllable and 
versatile rRBC membrane-inspired delivery platform, which may be used to overcome the deficiency of functionaliza-
tion in cell membrane coated nanoparticles .
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Background
Over the past few decades, red blood cells (RBCs or 
erythrocytes) based drug delivery systems have attracted 
considerable attention to improve the pharmacokinet-
ics, biodistribution and pharmacodynamics of therapeu-
tics or diagnostics [1, 2]. Commonly, administration of 
most therapeutic agents by conventional formulations 
and dosage may lead to the limited clinical applications 
and therapeutic index, which are due to their rapid clear-
ance and potential immunogenicity in vivo [3, 4]. In con-
trast, inherent biochemical and biophysical properties 
of erythrocytes make them a significant advantage over 
alternative technologies in terms of half-life, stability, 
versatility, safety and ease of manufacture as an ideal 
drug delivery platform [5–7]. Therefore, a variety of sub-
stances (e.g. enzymes, glucocorticoid analogs, immuno-
suppressant drugs, etc.) have been tried to be loaded in 
the erythrocytes for modulating their pharmacokinetics, 
and the encapsulated formulations also proved to be safe 
and to deliver the promise of a new technology capable of 
convenient solutions for old dilemmas.
Notably, numerous attempts have been tried to 
develop RBC membranes derived nanoparticles by uti-
lizing its functional features. For example, various nan-
oparticles, including polymeric nanoparticles [8],  Fe3O4 
nanoparticles [9], mesoporous nanoparticles [10], 
upconversion nanoparticles and gold nanocage and 
etc. [11, 12], have been coated with RBC membranes 
and then inherit its immune system evade ability to 
achieve long term circulation in blood. Further, RBC 
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to improve the properties of native RBC membranes 
derived nanoparticles, such as deformability, stability, 
targeting and circulation abilities. The strategies mainly 
include biomimetic rebuilding of RBCs, chemical modi-
fication on the membranes surface or inserting targeted 
ligand-linker-lipid conjugates into the membranes [13, 
14]. One potential adverse effect for these methods is 
the structural failure of membrane proteins, such as the 
self-recognition marker CD47 of preventing phagocy-
tosis by macrophages, consequently affecting its origi-
nal immune escape function [15, 16].
A key concept for preserving structural integrity is 
green technologies, which are defined as the elimina-
tion of hazardous substances and prevention of health 
impacts in the design process [17–19]. With utiliz-
ing this technology, the fabricated biomaterial system 
was expected to restore the natural structure to avoid 
membrane proteins damage. For example, Wang and 
co-workers reported a reconstituted lipoprotein nano-
particle (RLNs) using whole-components of endog-
enous lipids and native apolipoproteins to replace 
purified apolipoprotein and commercial lipids [20]. 
Inspired by the above pioneering studies wherein 
reconstituted structure was created via a green strat-
egy of “disassembly-reassembly”, we endeavored to 
construct a reconstituted RBCs (rRBCs) mimic that 
composed of isolated lipids and original proportions 
of endogenous proteins for reassembly, and finally pos-
sessed the complete features of native RBCs.
A pattern drug for demonstrating the above strategy 
in our biomimetic rRBCs is near-infrared (NIR) dye of 
IR780, which is a small organic molecules that absorb 
radiation in the wavelength range 700–1000 nm [21]. In 
the treatment of tumor, IR780 has been reported that it 
is a good candidate for the photodynamic therapy, pho-
tothermal therapy and NIR imaging due to its capability 
of generating a singlet oxygen, high photothermal con-
version efficiency and preferential accumulation in mul-
tiple tumor cells [22]. However, strong hydrophobicity 
and high toxicity of IR780 limit its further clinical appli-
cations [23]. Here, exploiting feasibility of this novel 
biomimetic green strategy of “disassembly-reassembly”, 
IR780 loaded rRBCs nanoparticles (IR780@rRBC) was 
fabricated with IR780@RBC and free IR780 as controls. 
The construction process of IR780@rRBC nanoparti-
cles was as shown in Fig. 1: ①RBCs membrane was first 
isolated and purified from nature RBCs; ②endogenous 
lipids and proteins were separated from the obtained 
RBCs membrane; ③the separated lipids were used to 
encapsulate IR780 by film dispersion method, ④and 
the original proteins of RBCs membrane were added to 
the film by hydration method for reassembly of IR780 
loaded rRBCs nanoparticles (IR780@rRBC).
In this study, we report and compare the solubility, 
toxicity, pharmacokinetics and pharmacodynamics of 
free IR780, IR780@RBC and IR780@rRBC. We expect 
the IR780@rRBC NPs formed by the above controlla-
ble and green assembly strategy to exhibit the superior 
performance in pharmacodynamics over IR780@RBC 
formed by a simple ultrasound method. And we secondly 
hypothesis that IR780@rRBC can improve the stability of 
IR780@RBC, and further contributing to the enhanced 
pharmacokinetics in  vivo due to the prolonged circula-
tion time. Based on these results, this controllable and 
green assembly technology will have variable applications 
in the functionalization of rRBCs derived nanoparticles 
because functional lipids can mix with isolated lipids 
in the reassembly process. Overall, rRBCs biomimetic 
show great potential to produce controllable and versatile 
RBC-inspired delivery platform for functionalize derived 
RBCs NPs in future study.
Materials and methods
Materials
IR780 was purchased from Sigma-Aldrich (St Louis, MO, 
USA). The mouse colon cancer cell line (CT-26) was pur-
chased from Shanghai Institute of Cell Biology (Shanghai, 
China). DAPI was purchased from Beyotime Institute of 
Biotechnology (Shanghai, China). The rabbit CD47 anti-
body were obtained from Cell Signaling Technology. All 
other reagents were from Nanjing Wanqing Chemical 
Glassware Instrument unless otherwise stated.
RBC membrane derivation
RBC membranes were obtained from nature RBCs fol-
lowing previously published protocols with modifications 
[24]. Briefly, whole blood was withdrawn from Balb/c 
mice and was centrifuged at 2000  rpm for 10  min at 
4  °C to collect the erythrocytes, which were continually 
washed with ice cold 1×PBS for three times. Then, the 
washed RBCs subjected into a hypotonic treatment with 
0.25×PBS in ice bath for 20 min, and subsequently cen-
trifuged at 8000 rpm for 15 min to remove the released 
hemoglobin. Finally, the obtained RBC membranes 
were washed with 1×PBS twice and were centrifuged at 
12,000 rpm for 10 min to get the RBC membrane.
Preparation of IR780@RBC and IR780@rRBC
IR780@RBC was prepared by an ultrasonic method. 
Briefly, the obtained RBC ghosts (1 mL whole blood) were 
sonicated for 10 min in a bath sonicator (50 kHz, 100 W). 
The resulting vesicles were subsequently extruded serially 
through 400-nm and then 220-nm polycarbonate porous 
membranes. Then the resulted RBC-Membrane-Derived 
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Vesicles were mixed with IR780 ethanol solution (1 mg/
mL) and sonicated again for 5 min. Then the final prod-
uct IR780@RBC was obtained by extruding through 220 
nm polycarbonate porous membranes to remove free dye 
and dialyzing against water to remove ethanol.
IR780@rRBC was prepared by a film dispersion method 
[25]. In brief, the dehydrated lipids (1 mL whole blood) 
and 1 mg IR780 were dissolved in 5 mL of ethanol and the 
organic solvent was evaporated under vacuum at 37 ℃. The 
dried lipid film was then hydrated with 2 mL of endogenous 
proteins solution (1 mL whole blood) at 37 ℃ for 30  min 
and sonicated at 100  W for 5  min. Then the final prod-
uct IR780@rRBC was obtained by extruding through 220 
nm polycarbonate porous membranes to remove free dye. 
Fig. 1 The scheme and procedure for the preparation of IR780 loaded reconstitute RBC membrane nanoparticles (IR780@rRBC NPs). A RBC 
membrane was prepared by a hypotonic method. Then RBC membranes were treated by mixed organic solvent, to separate the lipids and proteins. 
Lipids part was used to load IR780 by film dispersion method. At last, IR780@rRBC NPs were form by adding proteins with the film, following further 
extrusion. B IR780@rRBC NPs increased stability in vitro, and prolonged circulation capacity and enhanced PTT therapeutic efficiency in vivo
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Endogenous proteins and dehydrated lipids were isolated 
and purified from RBC ghosts using an organic solvent 
method similarly with the purification method from human 
plasma sample [26, 27]. Briefly, the obtained RBC ghosts 
were dissolved in PBS buffer (pH 5 ~ 6) and delipidated by 
adding equal volume of ethanol. After centrifugation, the 
supernatant was mixed with equal volume of ethanol and 
centrifuged again.  The final supernatant, which contained 
endogenous proteins and dehydrated lipids, was concen-
trated by polyethylene glycol (MW: 20,000) and dialyzed 
against PBS buffer, followed by precipitating dehydrated 
lipids with cold ethanol.
The preparation process of IR780@Liposome was 
similar to that of IR780@rRBC by using a film disper-
sion method. Briefly, 20 mg of Egg PC and 1 mg of IR780 
was dispersed in 5 mL ethanol, followed by evaporation 
for 30 min. After that, the dried lipid film was hydrated 
(2 mL distilled water), sonicated and extruded using the 
same condition as above to obtain IR780@Liposome 
system.
  SDS-PAGE was used to confirm the protein integrity 
of RBC membranes in IR780@RBC and IR780@rRBC 
nanoparticles. Western blotting was conducted to assess 
the presence of CD47 protein. The amount of the IR780 
in IR780@RBC and IR780@rRBC was determined by 
UV-VIS-NIR absorption spectra (UV1800, MAPADA) 
according to standard curve. IR780 encapsulation effi-
ciency was calculated as follows:
Characterization and stability of IR780@rRBC
Structure was examined using a transmission elec-
tron microscope (TEM, H-600, Hitachi, Japan). Particle 
size was determined by dynamic light scattering (DLS, 
Brookhaven, USA). Absorption spectra were recorded by 
UV-VIS-NIR spectro-photometer. The stability was eval-
uated by measuring the changed diameter in PBS buffer 
and serum at room temperature for up to 96 h. Long term 
stability was evaluated by measuring size of NPs before 
lyophilizing in 10 wt% sucrose solution and after resus-
pension. The amount of IR780 released from the IR780@
RBC and IR780@rRBC in PBS buffer was studied using 
the dialysis method.
Photothermal effect of IR780@rRBC
The obtained solutions of water, free IR780, IR780@
RBC and IR780@rRBC were irradiated with NIR laser 
(808 nm, 1 W/cm2), and the temperature was recorded 
every 10 s for 180 s using both a temperature detector 
Encapsulation efficiency(%)
= weight of IR780 in NPs/
weight of total added IR780× 100%
and an IR camera. The thermogenic capacity of above 
solutions was determined by repeated exposure to laser 
irradiation. Three cycles of irradiation were performed 
and the changed temperatures were recorded (808 nm, 
1 W/cm2, 4 min of each time).
Cytotoxicity
The cytotoxicity of IR780@rRBC NPs in CT-26 cells 
was measured according to a standard MTT assay at 
different incubation time. Briefly, the cells were seeded 
in 96-well plates (1 ×  104 cells per well) and cultured 
until reaching ∼80 % confluence. Then, the culture 
medium was replaced with a fresh medium contain-
ing different concentration of IR780, IR780@RBC or 
IR780@rRBC NPs, after incubation for 2  h, 8 or 24  h, 
the cell viability was measured by MTT assay at 490 
nm. For photothermal toxicity, the laser irradiation 
(1 W/cm2, 5 min) was performed to each well (8 or 24 h 
incubation) at 808 nm for one time, and then the cell 
viability was measured by MTT assay at 490 nm.
Macrophage cell uptake studies of IR780@rRBC NPs
To compare the stealth functionality of IR780, IR780@
RBC and IR780@rRBC NPs, mouse macrophage cell 
line RAW264.7 was chosen for cell uptake studies. Sim-
ply, the cells were seeded into 6-well plates (2 ×  105 
cells per well) in DMEM with 10 % FBS and 1 % penicil-
lin and streptomycin. After cells were reaching ∼60 % 
confluence, they were washed by PBS and replaced with 
fresh complete cell culture medium containing IR780, 
IR780@RBC or IR780@rRBC NPs (1.56  µg/mL for 
IR780) for 8 h incubation. Then, cells were washed with 
PBS and fixed with 4 % paraformaldehyde for 30  min. 
After fixation, cells were washed with PBS and stained 
with DAPI for 10  min. Finally, cells were washed with 
PBS again and imaged by confocal microscopy.
  In vivo pharmacokinetics studies
   Six-week-old female balb/c mice were used in compli-
ance with protocol approved by the Institutional Ani-
mal Care and Use Committee of Nantong University. 
For pharmacokinetics studies, fifteen male mice were 
randomly divided into free IR780, IR780@RBC and 
IR780@rRBC NPs groups (n = 5). The above formula-
tions were administered via intravenous injection with 
the IR780 dose of 1.4 mg/kg. At different time points (0, 
15 min, and 1, 2, 4, 8, 12, 24, 48, 72, 96 h), blood sam-
ples were collected by retro-orbital bleeding. The con-
tent of IR780 in the serum samples was measured using 
a Varioskan Flash Spectral Scanning multimode plate 
reader (Thermo Fisher Scientific, Waltham, MA, USA).
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  In vivo biodistribution and PTT therapeutic efficacy 
studies
For pharmacokinetics studies, 1 ×  107 CT-26 cells 
were subcutaneously injected into the right flank of 
each mouse. Two weeks later, the developed tumor 
was excised and cut into ∼1  mm3 pieces. The pieces of 
tumors were implanted into the right flank to establish 
subcutaneous tumors for the biodistribution and thera-
peutic studies.
Nine mice bearing xenograft tumor were used and 
divided into three groups (n = 3 per group) and were 
given a single dose of IR780@rRBC NPs (0.3  mg/kg 
IR780) by intravenous injection. Whole-body fluores-
cence imaging was performed using IVIS Lumina imag-
ing system (Xenogen Co., USA) with excitation/emission 
set to 745/808 nm. Fluorescence images were acquired 
in anesthetized animals at different time points (12 h, 24 
and 48 h). IVIS Living Imaging Software was used for the 
analysis of the amount of IR780 in tissues.
Therapeutic study started when the tumors reached 
∼200  mm3.The mice were divided into groups (n = 6 per 
group) and treated with (i) PBS, (ii) IR780 + NIR laser, 
(iii) IR780@RBC + NIR laser, (iv) IR780@rRNC NPs, (v) 
IR780@rRNC NPs + NIR laser. All samples were admin-
istered via Intravenous injection (1.4 mg/kg IR780). The 
day of administration was designated as day 0. After 24 h, 
the tumors were exposed to the NIR laser irradiation 
(1 W/cm2) for 3 min [28]. The temperature change of the 
tumor was recorded and imaged using a visual IR cam-
era (Fluke Corporation) at different time points for total 
250  s. Treatment administrations and laser irradiation 
were repeated on days 2 and 3. Tumor sizes and mouse 
body weights were recorded every other day. Tumor vol-
ume (V) was calculated as V =  d2 × D/2, where D and 
d are the longest and shortest diameter of the tumor, 
respectively.
Statistical analysis
Statistical assessment was conducted by two-sided Stu-
dent’s t test for two groups and one-way ANOVA analysis 
of variance for multiple groups (P < 0.05 was considered 
statistically significant). All analyses were performed with 
SPSS 19.0 for Windows.
Results and discussion
Preparation and characterization of IR780@RBC 
and IR780@rRBC
Several studies have reported that IR780 is tended to 
integrate with the hydrophobic parts of other compo-
nents based on its strong hydrophobicity [23]. Hence, 
IR780 was easily enclosed in the hydrophobic area of 
RBC membranes to form IR780@RBC NPs by an ultra-
sonic method. For the preparation of IR780@rRBC NPs, 
a standard film dispersion method was used to encap-
sulate IR780 with the isolated and dehydrated lipids in 
ethanol, and then the PBS buffer containing endogenous 
proteins were adding to form NPs after forming the film. 
To characterize the reconstituted IR780@rRBC NPs, the 
morphology and particle size of the free IR780, IR780@
RBC and IR780@rRBC were first measured by TEM 
and DLS. As shown in Fig.  2a, b, TEM images showed 
that IR780@rRBC NPs were more uniform and spheri-
cal compared with IR780@RBC NPs, and DLS results 
showed that the particle size of IR780@RBC and IR780@
rRBC NPs was 156.4 ± 16.8 and 80.28 ± 12.4 nm, respec-
tively. The inconsistent with the hydrodynamic diameter 
of IR780@RBC NPs obtained from TEM and DLS might 
be due to the increased IR780 concentration in the TEM 
dry process.
   To analyze the overall protein content of the IR780@
RBC and IR780@rRBC NPs, SDS-PAGE was used to run 
nature RBC membrane, IR780@RBC and IR780@rRBC 
nanoparticle formulations, followed by Coomassie stain-
ing for visualization. As shown in Fig. 2c, compared with 
RBC membrane, both nanoparticles had protein profiles 
that largely mirrored that of the corresponding mem-
brane. Additionally, CD47, a specific immunomodulatory 
protein marker responsible for immune escape property 
in RBC membrane, was carried out by western blot and 
the results showed that a near equivalent degree could 
be maintained after the formation of IR780@RBC and 
IR780@rRBC NPs (Fig.  2d). These results here indicate 
that our biomimetic green strategy of “disassembly-reas-
sembly” can bestow RBC surface proteins onto IR780@
RBC and IR780@rRBC NPs for expected long-circulating 
delivery.
The absorption spectrum of IR780@RBC and IR780@
rRBC NPs in Fig.  2e showed that IR780 was success-
fully incorporated into the RBC and rRBC membranes. 
The fluorescence spectra indicated that the distribution 
of IR780 was more uniformly via encapsulation into RBC 
membranes-based nanoparticles compared with free IR780 
and IR780@RBC, because they had relatively little fluores-
cence quenching in PBS solution induced by unfavorable 
aggregation (Additional file  1:  Figure S1). Encapsulation 
efficiency of IR780 in IR780@RBC and IR780@rRBC NPs 
was determined. The results showed that efficient load-
ing with a high encapsulation efficiency of 75.2 ± 3.5 % 
and 91.4 ± 6.4 % was achieved, and the relative IR780 con-
centration in IR780@RBC and IR780@rRBC NPs was 
750.2 and 910.4  µg/mL, respectively. Compared with the 
low solubility of free IR780 (0.4 µg/mL) in water [23, 29], 
the water solubility of IR780 was increased 1876-fold via 
encapsulation into RBC membranes-based nanoparticles, 
and its water solubility was further increased 2276-fold via 
encapsulation into rRBC membrane-based nanoparticles. 
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Additionally, the digital pictures of the IR780@rRBC 
NPs in water, PBS and 10 wt% sucrose further confirmed 
their good solubility (Additional file  1:  Figure S2). Taken 
together, these characterization data give strong physical 
evidence for successful loading IR780 into NPs wherein 
containing the properties of RBC membranes.
  In vitro stability and drug release of IR780@RBC 
and IR780@rRBC
  Considering the different preparation strategies of these 
two nanoparticles, a set of assays were carried out to 
assess nanoparticle stability in various media. To deter-
mine stability of the IR780@RBC and IR780@rRBC 
NPs in solution over time, samples were stored in either 
phosphate buffered saline (PBS, pH 7.4) or 100 % serum, 
and their sizes were measured over time. The IR780@
rRBC NPs exhibited stable size over a 96  h duration of 
the study in two media, while IR780@RBC NPs imme-
diately aggregated in PBS to ~320 nm and in serum to 
~700 nm (Fig.  3a, b). Regarding long term storage, the 
IR780@rRBC NPs formulation exhibited near identical 
size both before freeze-drying and after resuspension 
(Fig. 3c). In vitro release profiles of IR780 in PBS buffer 
were shown in Fig.  3d. The cumulative release of IR780 
from IR780@rRBC NPs was less than 20 % during 48 h, 
showing that IR780 was stably entrapped in the IR780@
rRBC NPs with low leakage in a simulated physiologi-
cal environment. In contrast, the cumulative release of 
Fig. 2 Characterization of IR780@RBC and IR780@rRBC NPs. a TEM images of IR780@RBC and IR780@rRBC NPs; b Size and zeta potential of IR780@
RBC and IR780@rRBC NPs; c SDS-PAGE of natural RBC membrane, IR780@RBC and IR780@rRBC NPs; d CD 47 expression of natural RBC membrane, 
IR780@RBC and IR780@rRBC NPs by western blot; e UV-VIS-NIR absorption spectra of natural RBC membrane, free IR780, IR780@RBC and IR780@
rRBC NPs
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IR780 from IR780@RBC NPs could be reached 70 % dur-
ing 48 h. Based on the improved stability and sustained 
release profile, we expect that IR780@rRBC NPs will 
decrease the toxicity and increase the tumor accumula-
tion of IR780 in the following experiments.
  In vitro photothermal, cytotoxicity and cellular uptake 
of IR780@RBC and IR780@rRBC
To assess the photothermal effect of IR780@RBC and 
IR780@rRBC NPs, the temperature was recorded by 
incubating them with the laser irradiation (1  W/cm2) 
for 3  min and the repeated irradiation for three cycles 
(1  W/cm2). From Fig.  4a, b, the temperature of free 
IR780 increased from ~ 30 ℃ to ~ 40 ℃ and decreased 
to ~ 35 ℃ in the third cycle. In contrast, IR780@RBC 
and IR780@rRBC NPs exhibited a higher temperature 
increase form ~ 30 ℃ to ~ 50 ℃ and slowed temperature 
decrease form ~ 30 ℃ to ~ 40 ℃ in the third cycle. Thus, 
these results demonstrated that the formation of nano-
particles could improve the photothermal properties of 
IR780, which might be due to the decreased degradation 
rate of IR780 in NPs. In addition, the photothermal effect 
of IR780@rRBC was also confirmed using an IR camera 
(Additional file 1: Figure S3). These results are consistent 
with previous reports of encapsulation IR780 into nano-
structured lipid carriers [22].
The cytotoxicity of IR780@RBC and IR780@rRBC 
NPs was then evaluated in CT-26 cells according to a 
standard MTT assays. As shown in Fig. 4c (Additional 
file  1:  Figure S2), the order of toxicity without laser 
irradiation was as follows: free IR780  >  IR780@RBC 
NPs > IR780@rRBC NPs, which reflected in the viability 
of cells treated with free IR780 at 6.25 µg/mL for 24 h 
declined to 25.07%, while the cell viability of IR780@
RBC NPs and IR780@rRBC NPs could be maintained 
at 55.91 and 75.48 %, respectively. In contrast, the order 
of toxicity with laser irradiation was as follows: IR780@
rRBC NPs  >  IR780@RBC NPs  >  free IR780, which 
reflected in the viability of cells treated with free IR780 
at 3.13 µg/mL for 24 h decreased to 24.62 %, while the 
cell viability of IR780@RBC NPs and IR780@rRBC NPs 
could be achieved at 14.29 and 8.49 %, respectively. Fur-
thermore, their cellular uptake was determined by flow 
cytometry and confocal microscopy, and the results 
Fig. 3 Nanoparticle stability. Z-average size of IR780@RBC and IR780@rRBC in PBS a and serum b over 96 h. c Z-average size of IR780@RBC and 
IR780@rRBC NPs before lyophilization in 10 wt% sucrose and after resuspension. d The release property of IR780@RBC and IR780@rRBC NPs in PBS 
buffer
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indicated that the internalization of IR780@rRBC was 
higher than IR780@RBC and free IR780 after 8 h incu-
bation (Fig. 4d, e). The above results demonstrated that 
IR780@rRBC and IR780@RBC NPs were low toxic 
compared with free IR780 before the laser irradiation 
due to their sustained release effect, although their cel-
lular uptake were higher compared with free IR780. 
However, their photothermal toxicity was enhanced 
after the laser irradiation due to the burst release 
induced by membrane rupture when compared with 
free IR780.
  In vivo characterization of IR780@RBC and IR780@rRBC
After confirming the superior stability and photothermal 
effect of IR780@rRBC NPs compared with free IR780 and 
IR780@RBC NPs, we investigated whether IR780@rRBC 
Fig. 4   In vitro photothermal and cytotoxicity. a Solution temperatures of different formulations with the laser irradiation (n = 3). b Thermal curves 
of different formulations after repeated laser irradiation (n = 3). c Cell viability of different formulations on CT26 cells at 24 h incubation with or 
without laser. Cellular uptake of different formulations determined by flow cytometry d and confocal microscopy e on CT26 cells for 8 h incubation
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NPs could inherit perfectly the stealth properties of RBC 
membrane, which reflected in effective escape in mac-
rophage cells, prolonged circulation time and improved 
tumor accumulation. To assess these, the macrophage 
uptake study was first used to evaluate the ability of 
IR780@rRBC NPs to escape the capture of macrophage 
cells. Additionally, IR780@Liposome system was also pre-
pared as a control group for comparing the macrophage 
escape ability. As shown in Fig. 5a, b, compared with free 
IR780, the IR780@RBC and IR780@rRBC NPs signifi-
cantly reduced the macrophage uptake and exhibited the 
weaker NIR fluorescence in RAW264.7 cells. In contrast, 
the IR780@Liposome exhibited enhanced cellular uptake 
due to the affinity between lipids and cell membranes. 
These results indicated that the IR780@RBC and IR780@
rRBC NPs inherited the immune system evade ability, 
Fig. 5 In vivo characterization. Cellular uptake of different formulations determined by flow cytometry a and confocal microscopy b on 
macrophage cells (Raw264.7) for 8 h incubation. c Blood circulation time of free IR780, IR780@RBC and IR780@rRBC NPs over a span of 96 h. d 
Biodistribution of free IR780, IR780@RBC and IR780@rRBC NPs 24 h after intravenous administration. All values are expressed as Means ± SD (n = 4)
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and had the potential to escape the endothelial system 
clearance for further in vivo applications.
One of the outstanding advantages for erythrocytes as 
delivery system is to extend the circulation time based on 
a variety of immunomodulatory markers expressed on its 
cell membrane [30, 31]. Hence, IR780@RBC and IR780@
rRBC NPs were expected to have longer circulation time 
compared with free IR780, which might resulted in the 
enhanced accumulation in tumor via EPR effects. To test 
this, in  vivo pharmacokinetics studies were conducted 
initially by administrating intravenously of free IR780, 
IR780@RBC and IR780@rRBC NPs in mice. The concen-
tration of IR780 in sampled blood was evaluated at indi-
cated time points, and our results (Fig. 5c and Additional 
file  1:  Table  S1) showed that the peak concentration 
 (Cmax) of IR780@rRBC, IR780@RBC and free IR780 was 
2.94, 3.13 and 2.04 µg/mL respectively. The area under the 
plasma concentration−time curve (AUC) was 1.77 and 
11.37 times higher in case of IR780@rRBC than IR780@
RBC and free IR780 (118.82 vs. 67.14 vs. 10.45 µg/mL*h). 
In comparison to the free IR780 or IR780@RBC, IR780@
rRBC also exhibited significantly prolonged half-life in 
the plasma  (t1/2) from 49.74 to 34.74 h (IR780@RBC) or 
7.98 h (free IR780). To analyze the bio-distribution, they 
were administered intravenously again, and the mice 
were sacrificed at 24  h after injection in order to col-
lect the heart, liver, spleen, lung, kidneys and tumor for 
IR780 concentration analysis. As shown in Fig. 5d (Addi-
tional file 1: Figure S5), IR780@rRBC NPs exhibited dra-
matic enhancement of tumor accumulation. Additionally, 
IR780@rRBC NPs also demonstrated significantly 
decreased accumulations within certain major organs 
compared to IR780@RBC NPs. These data indicate that 
the IR780@rRBC NPs prepared by this controllable and 
green assembly strategy significantly improve the circu-
lation time and tumor accumulation compared with free 
IR780 and IR780@RBC due to the nature properties of 
RBC membrane and the enhanced stability.
  In vivo photothermal therapy (PTT) of IR780@RBC 
and IR780@rRBC
Based on the improved circulation time and effective 
tumor accumulation of IR780@rRBC, we started to 
explore and compare the antitumor efficacy in tumor-
bearing mice treated with saline, free IR780, IR780@
rRBC and IR780@rRBC. First, we assumed that the accu-
mulation of IR780@rRBC NPs would produce higher 
temperature in tumor site than IR780@rRBC and free 
IR780, and then the temperature curve was recorded in 
the tumor region 24 h after administration following the 
laser irradiation. As shown in Fig. 6a, b, the tumor tem-
perature of IR780@RBC and IR780@rRBC NPs could 
reach ~ 60 ℃ and ~ 70 ℃ respectively, while the free 
IR 780 and saline groups showed slightly temperature 
increase to ~ 50 ℃ and ~ 40 ℃ respectively under the 
same laser conditions. Such a high temperature increase 
treated by IR780@RBC and IR780@rRBC NPs in the 
local tumor was expected to be sufficient to damage the 
tumor cells. H&E results exhibited significant necro-
sis of the tumors in the IR780@RBC and IR780@rRBC 
groups but not in any of the saline group (Fig. 6c). Anti-
tumor efficacy of the photothermal therapy with IR780@
rRBC was then studied and the mice were illuminated 
with laser irradiation at 24 and 72  h post-injection. As 
shown in Fig. 6d, e, combination of laser treatment with 
IR780@RBC and IR780@rRBC significantly suppressed 
the tumor volume compared with saline and free IR780 
groups, and the antitumor efficacy of IR780@rRBC was 
better than that of IR780@RBC treatment. Statistical 
results of tumor weight further confirming the superior-
ity of IR780@rRBC NPs prepared by our reported novel 
assembly biomimetic technology.
Finally, we evaluated whether treatment with the 
IR780@rRBC NPs possessed any potential toxic side 
effects (Additional file  1:  Figure S6a–c). Body weight 
change was used to detect the overall treatment-induced 
toxicity and no obvious weight changes were observed in 
any of the groups. ALT (alanine aminotransferase), AST 
(aspartate aminotransferase) for hepatic function, and 
UREA (urea nitrogen) and CREA (creatinine) for renal 
function, were evaluated in blood samples and no visible 
differences of the above enzymes could be find in saline 
and IR780@rRBC treated group. H&E staining of the 
main organs (heart, liver, spleen, lung, and kidney) fur-
ther confirmed safety of the treatment with IR780@rRBC 
NPs, as there were no apparent pathological changes 
compared with saline group. Overall, these findings sug-
gest that IR780@rRBC NPs is a safe therapeutic formula-
tion in photothermal anticancer therapies. 
Conclusions
In the present work, we reported a green “disassembly-
reassembly” strategy to construct biomimetic recon-
stituted RBCs membrane (rRBCs) whose composition 
comes from the endogenous proteins and lipids from 
nature RBC membrane. IR780, a NIR dye, was used as 
pattern drug to be loaded in rRBCs to form IR780@
rRBC NPs for demonstrating the benefits and feasibil-
ity of rRBCs with IR780@RBC NPs and free IR780 as 
controls. The properties of IR780@rRBC NPs, includ-
ing decreased toxicity and increased stability in  vitro, 
prolonged circulation capacity and enhanced PTT 
therapeutic efficiency in vivo, are improved, which may 
be due to the uniform distribution of IR780 in rRBC 
NPs through “disassembly-reassembly” strategy. These 
results indicate that the reconstituted rRBCs have 
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great potential to replace nature RBCs for developing 
RBC membranes derived nanoparticles. Additionally, 
the endogenous lipids can also be replaced or supplied 
by other functional lipids. Notably, when the endog-
enous proteins are reconstituted into the rRBC in the 
reassembly process, some proteins may be encapsulated 
into the aqueous core of rRBC. Therefore, the main 
functional proteins in reconstituted nanoparticles need 
to be determined for ensuring the endowed abilities, 
such as CD47 for RBCs. Overall, rRBCs biomimetic 
Fig. 6 Antitumor PTT activity of IR780@RBC and IR780@rRBC following intravenous administration in CT-26 colon cancer model. a Tumor 
temperature changes after laser exposure. b The infrared thermal images of mice using IR camera. c H&E stained tumor sections after PTT. Scale 
bars, 200 μm. d Tumor volume after different formulations with or without laser. e Tumor weight and representative tumor photograph after 
different formulations with or without laser
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represents a controllable and versatile RBC-inspired 
delivery platform compared with chemical synthesis 
and physical coating technology.
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